Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:41 PM
Ignite Modification Date:
2025-12-24 @ 4:41 PM
NCT ID:
NCT04608266
Eligibility Criteria:
Inclusion Criteria:
* Patients ≥ 18 years old
* Patients with an increased risk of severe COVID-19 belonging to one or more of the following groups :
* Age ≥ 50 years
* Body Mass Index ≥ 30 kg/m²
* Diabetes
* Hypertension
* Chronic renal failure (eGFR \<60 mL/min)
* Chronic heart disease
* Asthma/Chronic Obstructive Pumonary Disease/Cystic fibrosis
* Chronic liver disease
* Chronic neurological disease
* Solid organ transplant
* Bone marrow transplant
* Sickle cell anemia/ Major thalassemias
* Active or currently treated or \<1 year diagnosed cancer
* Active or currently treated or \<1 year diagnosed malignant blood disease
* Immunosuppressive treatment observed for more than 1 month
* Laboratory confirmed SARS-CoV2 infection with mild COVID-19, fulfilling all the following criteria:
* Positive SARS-CoV-2 RT-PCR nasal swab samples AND
* Clinical symptoms and signs consistent with SARS-CoV2 infection including but not limited to, fever, upper respiratory tract infection signs, digestive signs, muscle pain, anosmia, dysgueusia…(1)
* Informed consent to participate to the trial
* Patients must be able and willing to comply with study visits and procedures
Exclusion Criteria:
* Initial need for hospitalization for COVID-19 management
* Pregnancy and breastfeeding
* Participation to another interventional drug trial
* Subject protected by law under guardianship or curatorship
* Absence of health insurance
* Known hypersensitivity to camostat mesylate
* Known person sharing the same household already included in the study
* Participation to another COVID-19 ambulatory interventional study
* Patients having completed a full SARS-CoV2 vaccine immunization procedure less than 4 weeks prior to COVID-19 diagnosis (last vaccine injection performed less than 4 weeks prior to COVID-19 diagnosis)
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04608266
Study Brief:
Protocol Section:
NCT04608266